An open library pairing completed cancer trials with real-world emulations
Build a public collection where every major cancer trial has a matching analysis done on hospital data, so we learn exactly when real-world evidence can be trusted and when it cannot.
RCT-DUPLICATE calibrated real-world methods against trials mostly in cardiometabolic disease; oncology, with its time-varying treatments and surrogate endpoints, needs its own calibration set. The proposal funds a standing programme that emulates every phase 3 oncology trial with a real-world counterpart in federated data, publishes agreement metrics (direction, magnitude, confidence interval overlap), and maintains a public map of which question types (first-line comparisons, sequencing, dose) are emulable.
- Weak real-world evidence and registries · We do not reliably know what happens to patients after approval, so we cannot tell which drugs deliver in practice.
Pages like this
not linked directly; found by shared links- IdeaLinked prescribing and outcome data to find drug interactions with cancer therapy
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaWearable activity data as a validated real-world endpoint
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaNo mCODE, no payment: tie oncology reimbursement to a minimal structured record
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaGood practice standards and inspection for real-world data sources
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaOne international registry, not one per country, for conditional approvals
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaRequire genetic and target-trial evidence before funding any repurposing phase 3
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaAn automated pipeline emulating trials of every common drug against every cancer
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaReal-world dose intensity and toxicity monitoring to revise labelled doses
Shares Weak real-world evidence and registries, Real-world evidence.